Connor, Clark & Lunn Investment Management (CC&L)
HRTX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Heron Therapeutics HRTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-94,009
Closed -$122K – 1658
2025
Q4 		$122K Buy
94,009
+10,314
+12% +$12.7K ﹤0.01% 1475
2025
Q3 		$105K Buy
+83,695
New +$133K ﹤0.01% 1452
2023
Q1 		– Sell
-63,371
Closed -$158K – 1342
2022
Q4 		$158K Sell
63,371
-165,240
-72% -$532K ﹤0.01% 1081
2022
Q3 		$965K Buy
+228,611
New +$895K 0.01% 667
2022
Q2 		– Sell
-125,932
Closed -$720K – 1111
2022
Q1 		$720K Buy
+125,932
New +$922K ﹤0.01% 718
2015
Q2 		– Sell
-37,200
Closed -$541K – 636
2015
Q1 		$541K Buy
+37,200
New +$419K ﹤0.01% 385

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s HRTX Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 94,009 shares — an estimated $122K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in HRTX in Q1 2015 and held it in 6 quarters. The position peaked at $965K in Q3 2022. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 94,009 Heron Therapeutics shares in Q1 2026, an estimated $122K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Heron Therapeutics in Q1 2015 and held it in 6 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Heron Therapeutics position peaked at $965K in Q3 2022.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.